AB Science SA

1,2480

22-мая-25 06:40:31

15 мин. задержка

Акции

-0,0740

-5,60%

Сегодняшний диапазон

1,2480 - 1,3360

ISIN

FR0010557264

Источник

Cboe

AB Science today reports its revenues for the first half of 2023 and provides an update on its activities

29 сен 2023 10:49:30 Источник Nasdaq GlobeNewswire
AB Science provides an update on the EMA timetable for examination of the masitinib marketing authorization application in ALS

18 сен 2023 09:05:35 Источник Nasdaq GlobeNewswire
AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)

26 июн 2023 09:11:42 Источник Nasdaq GlobeNewswire
AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037

01 июн 2023 09:01:02 Источник Nasdaq GlobeNewswire
AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development Summit

17 май 2023 11:14:57 Источник Nasdaq GlobeNewswire
AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letter

09 май 2023 09:06:29 Источник Nasdaq GlobeNewswire
AB Science reports its revenues for the year 2022 and provides an update on its activities

28 апр 2023 09:41:27 Источник Nasdaq GlobeNewswire
AB Science - Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual Meeting

27 апр 2023 11:41:14 Источник Nasdaq GlobeNewswire
AB Science announces the success of its capital increase by private placement for an amount of 15 million euros

23 апр 2023 23:05:09 Источник Nasdaq GlobeNewswire
AB Science announces the implementation of a new strategy and the launch of a capital increase

21 апр 2023 13:26:19 Источник Nasdaq GlobeNewswire
AB Science announces masitinib patent granted in Japan for the treatment of amyotrophic lateral sclerosis, strengthening the Company’s intellectual property position until 2037

18 апр 2023 09:55:51 Источник Nasdaq GlobeNewswire
AB Science: Results of masitinib in ALS selected for a scientific platform presentation at the AAN 2023, including long-term survival analysis and a new analysis of patient population with no complete loss of function at baseline

12 апр 2023 09:23:23 Источник Nasdaq GlobeNewswire
AB Science announces that it has submitted its response to the day 120 questions in the EMA regulatory review of masitinib in amyotrophic lateral sclerosis and clarifies the new timeline for responding to Health Canada

04 апр 2023 09:10:02 Источник Nasdaq GlobeNewswire
AB Science will host a live webcast on its microtubule destabilizer agents (MDA) platform on Thursday March 16, 2023, from 6pm to 7pm CET

15 мар 2023 10:05:03 Источник Nasdaq GlobeNewswire
AB Science announced the publication of the masitinib pivotal phase 3 clinical trial in Alzheimer’s Disease in the journal Alzheimer's Research & Therapy

27 фев 2023 23:03:43 Источник Nasdaq GlobeNewswire
AB Science announces the drawdown of the second tranche of 6 million euros under its financing agreement with the European Investment Bank

31 янв 2023 09:17:01 Источник Nasdaq GlobeNewswire
AB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosis

29 дек 2022 09:08:58 Источник Nasdaq GlobeNewswire
Masitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in Switzerland

27 дек 2022 10:04:45 Источник Nasdaq GlobeNewswire
AB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment Bank

22 дек 2022 09:10:29 Источник Nasdaq GlobeNewswire
AB Science receives Notice of Deficiency (NOD) from Health Canada for masitinib in the treatment of amyotrophic lateral sclerosis (ALS)

13 дек 2022 09:08:12 Источник Nasdaq GlobeNewswire

<<
<
1
2
3
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.